Atara Biotherapeutics, Inc. (ATRA): restructuring charge — Atara Biotherapeutics cuts workforce by ~50%; expects $7.5M severance costs

Atara Biotherapeutics, Inc.

Workforce reduction impacts ~50% of current employees; completion expected by June 2025.
Estimated severance and related benefits of approximately $7.5 million, primarily one-time cash charges.
Additional details to be disclosed in Q1 2025 Form 10-Q.
Company may incur other charges not currently contemplated from the reduction.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $7.5 million in total for severance and related benefits affecting workforce (approximately 50% of its current employees).

Type: restructuring
Charge: approximately $7.5 million in total for severance and related benefits
Affected area: workforce
Headcount: approximately 50% of its current employees

Exact text from the filing

On January 27, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 50% of its current employees. The Company expects to substantially complete the workforce reduction by June 2025. The Company expects to recognize approximately $7.5 million in total for severance and related benefits for employees laid off under the reduction in force.

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-009225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.